LFCR

In the past six months, Lifecore Biomedical's stock has seen a 48.16% rise over the last month and a 52.84% increase over the last six months as of October 11, 2026. However, as of September 18, 2026, the share price had declined by 43.40% over the past year. A major event was the announcement on September 28, 2026, that Lifecore Biomedical entered into a definitive agreement to be acquired by Webster Equity Partners for up to $663.7 million. Common stockholders are set to receive $6.28 per share in cash at closing, representing an approximately 49.5% premium, plus Contingent Value Rights (CVRs) for up to $160 million in aggregate cash payments contingent upon achieving performance milestones in 2028, 2029, and 2030. This acquisition has led to several shareholder alerts and investigations by law firms concerning the fairness of the buyout valuation. The transaction is expected to close at the end of the fourth quarter of 2026, subject to stockholder and regulatory approvals. The company also reported its second-quarter 2026 financial results on August 5, 2026, with revenues decreasing by 6.2% compared to the prior year, though Lifecore reaffirmed its 2026 guidance and highlighted multiple new business wins.